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We evaluated PCR methods for diagnosis of acute and chronic cutaneous leishmaniasis (CL) in an area of
Colombia where Leishmania (Viannia) is endemic. The PCR method specifically amplified whole linearized
minicircle kinetoplast DNA (kDNA) of the Leishmania subgenus Viannia from biopsy lysates. PCR products
were detected in agarose gels. For 255 acute cases, this PCR method had greater sensitivity (75.7%) than each
conventional method, i.e., microscopic examination of Giemsa-stained lesion scraping (46.7%), biopsy culture
(55.3%), aspirate culture (46.3%), and the conventional methods combined (70.2%). Among 44 cases of chronic
CL, amplification of biopsy DNA was more sensitive (45.5%) than the individual (4.5 to 27.7%) and combined
(27.3%) conventional methods. The detection of kDNA in biopsies from chronic lesions was enhanced by a
chemiluminescent dot blot hybridization, which produced a sensitivity of 65.8% when alone and 90.9% when in
combination with DNA extraction of biopsy lysates (P < 0.001). Three biopsies from 84 skin lesions of other
etiologies were falsely positive by PCR (specificity, 96.4%). PCR detected kDNA more frequently in biopsies
(detection level, 83.9%) than in aspirates (74.7%) from 103 cases of acute CL. Among aspirates from 53 chronic
cases of CL, the alternative methods, DNA extraction and hybridization, increased sensitivity from 41.5 to
56.6% (P > 0.05). This enhanced PCR method in chronic biopsies was so much more sensitive than conven-
tional methods that it should be considered the preferred diagnostic method for chronic CL. These findings
support the appropriate incorporation of PCR into diagnostic strategies for cutaneous leishmaniasis.
The leishmaniases are a group of illnesses of the skin, oral
and respiratory mucosae and the reticuloendothelium caused
by protozoa of the genus Leishmania. Of these, the cutaneous
form is the most widespread, afflicting primarily rural and
periurban populations exposed to the infected sand fly vector.
Cutaneous leishmaniasis (CL) is most frequently diagnosed by
clinical evaluation, either alone or in combination with the
leishmanin skin test. Clinical evaluation usually suffers from
lack of standardization (13, 38) and is hampered by the fact
that even fairly typical acute lesions can be confused with other
dermatological problems, such as sporotrichosis (9). The leish-
manin skin test is highly sensitive but lacks specificity when
employed in areas of endemicity because it cannot distinguish
acute lesions from past infection. A definitive, laboratory di-
agnosis of mucosal or cutaneous leishmaniasis traditionally
requires either the visualization of amastigotes or the isolation
of replicative Leishmania from lesions (24). The most widely
employed laboratory methods for CL are microscopic exami-
nation of lesion scrapings, biopsy impression smears, and his-
topathology. The most sensitive conventional diagnostic meth-
ods, culture of lesion biopsies and aspirates, are available only
in reference laboratories. Even these less available, more sen-
sitive methods are positive in only 70 to 75% of acute cases
when optimally performed (21, 38).
Due to these difficulties several new approaches to the di-
agnosis of CL were developed, including DNA probes and
PCR (15, 29, 31). Of these, the PCR method is the most
promising (43). The minicircle of kinetoplast DNA (kDNA)
and ribosomal DNA are ideal targets for amplification because
they are present in multiple copies and have both conserved
and variable regions (7, 18, 31, 36). Primers that amplify either
segments of kDNA or the entire minicircle have great poten-
tial as diagnostic tools because they detect minute quantities of
DNA and as little as 1/10 of a cultured Leishmania organism
(7, 29). When applied to patient samples the PCR continues to
show promise as a practical and sensitive diagnostic tool for CL
(2, 8, 16, 20, 26, 30).
Despite these encouraging findings, essential questions re-
main to be solved before PCR can be incorporated routinely
into diagnostic protocols for CL. Working with a large group of
well-characterized patients, we addressed the following ques-
tions. (i) To what extent does PCR improve upon three cur-
rently available, conventional diagnostic methods for CL? (ii)
When the PCR is positive but conventional methods are neg-
ative, do these patients truly have leishmaniasis or are the PCR
results falsely positive? (iii) Does the type of specimen (biopsy
or aspirate) affect the PCR results? (iv) How does PCR per-
form in detecting Leishmania spp. in chronic lesions? (v) How
did alternative methods of sample preparation and product
detection affect clinical performance of the PCR in chronic
CL? We emphasized the application of PCR to chronic lesions
because these patients provided the greatest diagnostic chal-
lenge. Chronic lesions are easily misdiagnosed by clinical cri-
teria because they are often atypical, giving rise to terms such
as carcinoma-like, lupoid, sporotrichoid, and verrucoid leish-
maniasis (9, 23, 42). Moreover, due to the low density of
Leishmania in chronic disease, conventional laboratory meth-
ods are much less sensitive in detecting the protozoans in
lesions of more than 6 months’ duration (38). Because we were
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interested in PCR methods that could be most readily used in
settings of high endemicity, we utilized amplicon detection
methods that did not require radioactive reagents and used
relatively simple sample preparation methods.
MATERIALS AND METHODS
Study design. The sensitivities of PCRs and three conventional methods for
diagnosis of CL were compared against a reference standard used to identify
cases of CL among those evaluated, because none of the conventional methods
is sufficiently sensitive to serve as a reference standard (28; W. C. Miller, Reply
to letter, Clin. Infect. Dis. 27:1186–1193, 1998). The reference standard for cases
of leishmaniasis consisted of combined laboratory criteria (conventional labora-
tory methods or supplemental laboratory methods) and previously evaluated
clinical criteria (40). A case of CL was required to meet either the laboratory or
the clinical criteria. For calculation of sensitivity the unit of analysis was the
patient, not the specimen or test. The numbers of cases of CL identified by the
reference standard provided the denominators of the sensitivity calculation. A
case of CL was considered to be test positive for the tests being compared, PCR
and the conventional methods, only if the specimen obtained during the patient’s
first pretreatment evaluation was positive. The numbers of these test-positive
cases of CL provided the numerators of the sensitivity calculations.
Study population. All patients who presented to the CIDEIM clinics in Cali or
Tumaco, Colombia, for diagnosis of their skin lesions between 30 August 1990
and 20 April 1994 were evaluated by clinical scores and by the conventional
diagnostic methods prior to receiving antileishmanial treatment. Altogether 299
patients met the reference standard for CL and the inclusion criterion that their
first specimens were evaluated by all three conventional diagnostic methods and
PCR. Of these, 255 presented with acute lesions while 44 presented with chronic
lesions.
Patients who did not meet the criteria of the reference standard could not be
considered noncases due to the small possibility that they had undiagnosed
leishmaniasis. Therefore, we identified a group of 84 noncases among those who
presented either to the CIDEIM clinic in Cali for suspected leishmaniasis or to
the Dermatology Clinic of the Hospital Universitario del Valle for evaluation of
skin lesions due to other causes. The criteria for noncases were negative con-
ventional exams for leishmaniasis, never having resided in an area where leish-
maniasis is endemic, a negative reaction to the leishmanin skin test (39), and a
laboratory-confirmed diagnosis of another etiology of their skin lesions. These
other causes included sporotrichosis, leprosy, seborrheic keratosis, vascular ul-
cer, and basocellular carcinoma.
Specimen collection. After explaining the study and obtaining the patient’s
consent, a standardized history was recorded, a physical exam was performed,
and the following samples were obtained as previously described (9, 24): four
lesion scrapings, eight lesion aspirates, and two punch biopsies. Dermal scrapings
were air dried, fixed in methanol, Giemsa stained, and examined for amastigotes
under oil immersion. Four randomly chosen aspirates were cultured in Senekjie’s
medium; the other four were pooled and frozen at 70°C for later evaluation by
PCR. One randomly chosen biopsy was fixed in formalin and examined as
needed to confirm other etiologies. The other biopsy was divided longitudinally
and randomized, and one half was processed for Leishmania culture, while the
other half was stored at 70°C. Specimens collected for PCR in Tumaco were
stored at 4°C and transported by air and frozen within 24 h.
Diagnostic methods. The three conventional methods, Giemsa-stained lesion
scrapings, culture of lesion aspirates, and macerated biopsies in Senekjie’s media
(9, 24, 33), and PCRs were performed on clinical specimens collected during
each patient’s initial diagnostic evaluation. Bacterial contamination of Leishma-
nia cultures was minimized by treating patients with obviously purulent or im-
petiginous lesions with systemic antibiotics and local debridement before obtain-
ing specimens, by cleansing lesions with 70% alcohol, by using sterile procedures
for biopsies and aspirates, and by adding penicillin G and streptomycin to the
phosphate-buffered saline solution utilized in the aspiration and the biopsy
maceration.
In order to apply the reference standard and thereby identify additional cases
of CL, supplemental laboratory procedures were performed and clinical predic-
tion rule criteria established in a prior study (40) were utilized when all conven-
tional methods were negative for the initial clinical sample. The additional
specimens were obtained and evaluated by the three assays described above and
by inoculation of macerated biopsies into hamsters. Supplemental laboratory
results were not used to determine if a case of CL was test positive. The clinical
criteria for the reference standard were met if either of two previously evaluated
scores was above their cut points: the Clinical__Historical__MN (Montenegro
skin test) score (15) or the Clinical__Historical score (12). The variables used
to calculate these scores were collected on a standardized form using uniform
definitions.
Preparation of specimens for PCR testing. One-fourth of each 4-mm-diameter
punch biopsy was vortexed in 25 l of lysis buffer (10 mM Tris-HCl [pH 8.0], 10
mM EDTA, and 50 g of proteinase K [Boehringer-Mannheim]) for 10 s,
digested at 65°C for 2 h, and then boiled for 15 min; the debris was sedimented
at 12,000  g for 10 min (37). The supernatants were diluted 1:10 in Tris-EDTA
(TE) buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA) and stored at 20°C. Fifty
microliters of lesion aspirates was precipitated at 12,000  g for 10 min. The
pellet was resuspended in 30 l of the lysis buffer containing 80 g of proteinase
K, and then it was lysed, diluted, and stored as described for biopsies. As an
alternative method for sample preparation, we extracted DNA from selected
biopsy and aspirate lysates using a rapid phenol-chloroform-isoamyl alcohol
(25:24:1) extraction and precipitation in ethanol with 250 mM sodium acetate
and 1 g of glycogen per l (32). The remaining pellet was dried in a vacuum
desiccator and dissolved in 10 l of TE buffer, and 1 l (1 to 10 pg) of DNA was
added to PCR vials.
Positive controls of kDNA were prepared from promastigotes of Leishmania
(Viannia) braziliensis World Health Organization reference strain no. MHOM/
BR/75/M2904, grown in Schneider’s Drosophila medium at 28°C for 5 days, and
extracted as previously described (24). To examine the specificity of these prim-
ers, kDNA was similarly extracted from Leishmania reference strains and Co-
lombian Leishmania isolates.
PCR conditions. After the PCR conditions were optimized, as described in
Results, the following routine methods were used for processing lysates and
DNA extracts and compared to alternative methods. B1 and B2 primers used in
this study specifically amplify the entire kDNA of Leishmania (Viannia) to a
750-bp band product (7). A reaction mixture was prepared in a 50-l final
volume containing 50 mM KCl, 1.5 mM MgCl2, 10 mM Tris-HCl (pH 8.3), 0.01%
gelatin, a 0.2 mM concentration of each deoxyribonucleotide, 100 pmol of each
primer, 2.5 U of Ampli-Taq DNA polymerase (Perkin-Elmer Cetus or Boehr-
inger Mannheim), and either 3 l of diluted biopsy lysate or 10 l of diluted
aspirate lysate. PCR amplification was carried out in a DNA thermal cycler (MJ
Research) with a hot-start step to denature DNA for 5 min followed by 35 cycles
of 95°C for 30 s and 60°C for 1 min and then a final prolonged cycle of 95°C for
1 min, 60°C for 3 min, and 72°C for 3 min. In the routine assays, 10 l of the
amplification products was analyzed by agarose gel electrophoresis, ethidium
bromide staining, and visualization under UV light and recorded on Polaroid
film (8).
Precautions taken to avoid contamination during specimen collection included
use of disposable gloves, vials, biopsy punch, needles, syringes, and scalpels and
use of DNA-free solutions. The risk of amplicon contamination was minimized
by designating four separate areas as already described (11). Lots of PCR
mixture were prepared, tested for contamination by PCR, and stored at 20°C
in aliquots, to avoid repeated handling.
The detection limit of the PCR was monitored with low-copy-number positive
controls, 1.0 and 0.1 fg of kDNA, in each assay. If a PCR product appeared less
dense than the product of the 0.1-fg positive control, it was considered to be
weakly positive and the assay was repeated. Only those products that remained
weakly positive or positive on repeat testing were considered positive. A negative
control consisting of the reaction mixture was tested for every 15 clinical speci-
mens to monitor contamination. In each assay up to 30 clinical specimens (which
always included negative specimen controls [3] from noncases) were evaluated
without knowledge of patient number, group, or the results of other diagnostic
methods, by assigning random numbers to each specimen.
Dot blot hybridization and chemiluminescent detection. The probe was pre-
pared from kDNA, extracted from amplification product of L. (V.) braziliensis
promastigotes, labeled with biotin using random primers according to the man-
ufacturer’s instructions (BIO-PRIME labeling system; GIBCO-BRL, Grand Is-
land, N.Y.). We denatured 25 l of PCR products with an equal volume of 0.5
M NaOH–1.5 M NaCl for 10 min at room temperature, neutralized them with 50
l of 2 M ammonium acetate (pH 8.0) on ice for 10 min, and then spotted them
onto a nylon membrane (GIBCO -BRL) presoaked in water. The DNA was fixed
to the membranes by UV cross-linking. Prehybridization and hybridization con-
ditions were performed under conditions recommended by the manufacturer
(Photogene Nucleic Acid Detection System; GIBCO-BRL), and results were
visualized on X-ray film.
Data analysis. Results of clinical evaluation, diagnostic tests, and PCR were
analyzed using Statistical Package for the Social Sciences software. The sensi-
tivity (test positives/cases of CL identified by reference standard) of PCR of
specimens taken during the patients’ first evaluations was compared to that of
each conventional method. The sensitivity of PCR was also compared to the
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sensitivity of the combined conventional methods. The combined conventional
methods were considered test positive if any of the three conventional methods
was test positive. The group of noncases served to identify false-positive PCR
results and estimate the specificity of the routine PCR (test negative/noncases).
Statistical methods included estimation of sensitivity and specificity as described
above and comparing the sensitivity of PCR with that of other methods using the
McNemar chi-square test, because the pairs of tests were performed on speci-
mens from the same patient (10). One-sided hypothesis tests were performed to
test the hypothesis that the routine PCR was more sensitive than the individual
and combined conventional methods.
RESULTS
Biological specificity. These primers were previously dem-
onstrated to amplify four species (panamensis, peruviana, bra-
ziliensis, and guyanensis) of Leishmania subgenus Viannia but
not Leishmania subgenus Leishmania amazonensis, L. (L.)
mexicana, L. (L.) tropica, L. (L.) major, L. (L.) chagasi, L. (L.)
donovani, or L. (L.) infantum (7). We confirmed these speci-
ficities and also demonstrated that these primers did not am-
plify human DNA or the DNA from pathogens in the differ-
ential diagnosis of CL: Sporothrix schenkii, Trypanosoma cruzi,
Escherichia coli, Staphylococcus aureus, Mycobacterium tuber-
culosis. To assess whether these primers amplified all Leish-
mania (Viannia) organisms from this region of Colombia, they
were evaluated with lysed promastigotes of 10 strains of L. (V.)
guyanensis, 45 strains of L. (V.) panamensis, and 11 strains of L.
(V.) braziliensis, which represent the range of enzyme variants
isolated from Colombian patients. Only 2 of these 66 strains
were not amplified even after repeat testing; both were L. (V.)
panamensis.
Optimization of PCR. Amplification of 126 lysates of lesion
biopsies indicated that detection limits lower than the 1 to 10
fg reported earlier (7) would be needed. This was achieved by
beginning the PCR with a hot start to ensure complete dena-
turation prior to the first prolonged annealing cycle (25), in-
creasing the number of cycles from 30 to 35 and prolonging the
last cycle to 3 min each of annealing and extension. These
enhanced conditions consistently amplified 0.1 fg of kDNA.
Forty-one biopsies from cases of CL sensitivity increased from
44 to 78% (P  0.0015). These modified PCR conditions were
employed in subsequent routine amplifications.
PCR of skin biopsies. The sensitivity of the routine PCR
method for lesion biopsies was compared with that of each of
the three conventional methods and of the methods combined
(Table 1). Because the conventional methods are known to be
less sensitive in chronic lesions, i.e., of 6 or more months’
duration (38), the comparisons are presented separately for
patients with acute and chronic lesions. For acute CL, the PCR
was much more sensitive than any single conventional method.
The sensitivity of the PCR (75.7%) was slightly greater than
that of the conventional methods combined (70.2%) in acute
CL. However, for chronic CL the sensitivity of PCR (45.5%)
far exceeded the sensitivities of both the single and combined
conventional methods, which ranged from 27.3 to 4.5%. Inclu-
sion of the clinical score as a criterion for the reference stan-
dard allowed the assessment of the gain in sensitivity afforded
by PCR in 65 cases of CL that were negative by both conven-
tional and supplemental laboratory methods. Bacterial con-
tamination was observed in the aspirate and/or biopsy cultures
of only 10 of the 108 patients with negative results by the
combined conventional methods.
Among the biopsies from the 84 patients with diagnoses
other than leishmaniasis, three specimens were considered to
be false positives: two positives and one weakly positive that
remained weakly positive on repeat testing, resulting in an
overall specificity of 96.4% (81/84) for this PCR. In order to
understand the origin of these false positives, both stored ly-
sates and newly prepared lysates were retested. Two of the
three stored lysates were weakly positive when retested, but
none of the three fresh lysates were positive, indicating that
contamination had occurred during lysate preparation or use,
but not during sample collection.
Alternative PCR methods for biopsies. In order to achieve a
greater sensitivity of the PCR for chronic lesions, we employed
DNA extraction and chemiluminescent dot blot hybridization
FIG. 1. Analysis of PCR products by chemoluminescent dot blot
hybridization. Dot 1, PCR control; dots 2 and 3, PCR products of 1.0
fg and 0.1 fg, respectively, of Leishmania (Viannia) kDNA; dots 4 to 12,
PCR products from biopsy lysates of chronic lesions of patients 1847,
2996, 1791, 1813, 1837, 1839, 4055, 2932, and 4091, respectively. Dots
1 and 8 were read as negative; the remainder were read as positive.






% Sensitivity (no. of cases testing positivea/no. of cases evaluatedb)
PCR Lesion scraping Biopsy culture Aspirate culture Conventionalmethods combined
6 Laboratory 83.9 (177/211) 56.4c (119/211) 66.8c (141/211) 55.9c (118/211) 84.8 (179/211)
6 Clinical score 36.4 (16/44) 0.0c (0/44) 0.0c (0/44) 0.0c (0/44) 0.0c (0/44)
6 Combined 75.7 (193/255) 46.7c (119/255) 55.3c (141/255) 46.3c (118/255) 70.2d (179/255)
6 Laboratory 60.9 (14/23) 8.7c (2/23) 43.5 (10/23) 34.8d (8/23) 52.2 (12/23)
6 Clinical score 28.6 (6/21) 0.0c (0/21) 0.0c (0/21) 0.0c (0/21) 0.0c (0/21)
6 Combined 45.5d (20/44) 4.5c (2/44) 22.7c (10/44) 18.2c (8/44) 27.3d (12/44)
a No. of patients whose lesions were test positive by one or more of the three conventional methods.
b No. of patients who were evaluated initially by all three conventional methods (lesion scraping, biopsy culture, and aspirate).
c P  0.01, McNemar chi-square test, comparison with PCR.
d P  0.05, McNemar chi-square test, comparison with PCR.
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(Fig. 1). When the PCR products were evaluated by this hy-
bridization dot blot, the PCR detection limit was consistently
0.01 fg of kDNA. We compared two options for detection of
the PCR products: the dot blot hybridization and the routine
agarose gel in combination with two sample preparation meth-
ods, DNA extraction and the routine method, a diluted lysate.
Detection of the products by dot blot hybridization improved
the sensitivity of the PCR, regardless of how the sample was
prepared (Table 2), whereas DNA extraction improved sensi-
tivity only when the product was detected by dot blot.
PCR of lesion aspirates. Because biopsy specimens are in-
vasive and sometimes unaccepted (14, 17), we also evaluated
aspirate specimens as PCR targets. After trials of several al-
ternatives for sample preparation, we selected the method of
diluting the aspirate lysates 1:10 in TE buffer and adding 10 l
of the diluted lysate to the PCR vial because undiluted aspirate
lysates were very inhibitory, presumably due to their high he-
moglobin content. This routine method amplified the target
kDNA in 80 of 103 (77.7%) aspirates from a random sample of
cases of CL but in none of the aspirates for nine noncases.
Among aspirates from patients with acute CL this routine PCR
was more sensitive than the lesion scraping and aspirate cul-
ture methods (Table 3). PCR detected kDNA more frequently
in biopsies (83.9%) than in aspirates (74.7%) from these 103
cases of acute CL (P  0.05). For cases of chronic CL, PCR of
aspirate samples did not improve upon the low sensitivity of
conventional methods.
Alternative methods for lesion aspirates. We examined the
effect of DNA extraction in combination with two methods for
amplicon detection (either dot blot hybridization or the rou-
tine agarose gel) on the PCR results of aspirates from 53
chronic lesions (Table 2). The net effect of these three alter-
natives was an increased sensitivity, ranging from 50 to 56%,
relative to the 40% sensitivity of the routine PCR of aspirates
from chronic CL cases.
DISCUSSION
We modified an existing PCR method and determined the
extent to which PCR could improve upon the sensitivity of
conventional diagnostic methods for CL. Because diagnosis is
more challenging for chronic CL, we examined the perfor-
mances of PCR methods separately for acute and chronic
cases. We emphasized detection of kDNA in biopsy specimens,
because these are more frequently obtained in areas where
leishmaniasis is endemic. For acute CL, the routine PCR
method applied to biopsies was more sensitive than each of the
three individual conventional methods and the combination of
the three conventional methods. PCR of biopsies from chronic
lesions was twice as sensitive as conventional methods. DNA
extraction and product detection by a dot blot hybridization
greatly enhanced the ability of this PCR to detect kDNA in
chronic lesions. This enhanced PCR method was so much
more sensitive than conventional methods that it should be
considered the preferred diagnostic method for chronic CL.
The advantages of PCR for the detection of Leishmania is
most striking in clinical specimens with scarce amastigotes, for
which conventional methods are very insensitive. PCR de-
tected Leishmania (Viannia) in scars of healed treated cases of
CL (34). Pirmez et al. found PCR to have its greatest impact in
the diagnosis of mucosal lesions, where conventional methods
are very insensitive due to the paucity of amastigotes and
frequency of bacterial contamination (26). Diagnosis of
chronic CL of the Old World, lupoid leishmaniasis, caused by
L. major and L. tropica, is also hampered by the scarcity of
amastigotes. A PCR method using paraffin-imbedded biopsies
was reported to detect kDNA in 53% of 20 culture-positive
cases and 48% of clinically suspect cases of lupoid leishmani-
asis (19). The PCR method was more sensitive than histopa-
thology. Half of the false-negative PCRs were attributed to
poor stability of DNA in paraffin-imbedded biopsies.
The two types of specimens useful for the diagnosis of CL,
aspirates and biopsies, have not been previously compared as
targets for PCR. For acute CL, PCR of aspirates was more
sensitive than two conventional assays; however, PCR detected
kDNA more frequently in biopsies than in aspirates. There-
fore, aspirates should be used as amplification targets only for
patients with acute CL for whom biopsy is unacceptable or not
feasible (4). For acute CL, dermal scrapings from the bottom
of the ulcer may yield viable specimens for PCR, although
TABLE 2. Alternative methods for sample preparation and




No. of cases testing
positive by PCR/no. of
cases evaluateda (%)
Biopsy Diluted lysateb Agarose gelb 15/33 (45.5)
Diluted lysate Dot blot 21/33 (63.6)
DNA extract Agarose gel 13/33 (39.4)
DNA extract Dot blot 30/33(90.9c)
Aspirate Diluted lysateb Agarose gelb 22/53 (41.5)
Diluted lysate Dot blot 27/53 (50.9)
DNA extract Agarose gel 28/53 (52.8)
DNA extract Dot blot 30/53 (56.6)
a No. of cases evaluated initially by all three conventional methods.
b Routine methods.
c In chi-square test for multiple proportions, P  0.01 compared with all other
combinations of biopsy sample preparation and product detection methods.





% Sensitivity (no. of cases testing positivea/no. of cases evaluatedb)
PCR Lesion scraping Biopsy culture Aspirate culture Conventional methods combined
6 Laboratory 77.7 (80/103) 46.6c (48/103) 68.9 (71/103) 58.3c (60/103) 87.4 (90/103)
6 Laboratory 38.1 (8/21) 4.8c (1/21) 42.8 (9/21) 33.3 (7/21) 52.4 (11/21)
a No. of patients whose lesions were positive by one or more of the three conventional methods.
b No. of patients who were evaluated initially by all three conventional methods.
c P  0.01, McNemar chi-square test, comparison with PCR.
604 WEIGLE ET AL. J. CLIN. MICROBIOL.
results of this method have not been compared with those
obtained with other types of specimens (27).
The lack of an ideal “gold standard” for CL poses problems
for estimating the sensitivity and specificity of PCR methods
(27, 43; Miller, reply to letter). Some studies have used all
suspect cases as the gold standard (16, 26, 30), which may be of
low sensitivity and low specificity, depending on the diversity of
clinical cases (12). Others have used conventional methods,
which lack sensitivity (6, 27). Because PCR methods can have
extremely low detection limits, they can detect kDNA in spec-
imens that are negative by conventional methods. If insensitive
conventional methods are used to define cases, then the po-
tential gain in sensitivity afforded by PCR cannot be deter-
mined. The question “When the PCR is positive but the con-
ventional methods are negative, does the patient have
leishmaniasis or is this a false-positive PCR?” is challenging.
Discrepant analysis, which uses a third assay to decide these
discrepant cases, is frequently employed but is inherently bi-
ased (6; Miller, reply to letter). We reduced these problems by
recognizing that the conventional methods were inadequate
reference standards. Instead, we defined a reference standard
that followed guidelines for an expanded gold standard (Mill-
er, reply to letter) and exploited the strength of multiple tests:
conventional assays, supplemental laboratory assays, and a sen-
sitive clinical score. As recommended, this reference standard
was applied to all patients, not only to discrepant cases. To
assess specificity we identified a group of noncases that had
lesions caused by other etiologies.
The relative gain in sensitivity achieved by PCR varies ac-
cording to the conventional methods to which this procedure is
compared (4). When compared to microscopic methods re-
quiring abundant parasites, the PCR uniformly produces a
marked gain in sensitivity (16, 30). When compared to Leish-
mania culture, the relative gain in sensitivity achieved by PCR
depends on the degree to which culture contamination was
avoided. In four studies in which cultures were frequently
contaminated, PCR appeared much more sensitive than cul-
tures (16, 26, 30, 34). Our measures to decrease bacterial
contamination of cultures may have increased the sensitivity of
culture methods and minimized relative gain in sensitivity
achieved by PCR to a degree that cannot be generalized to
many settings.
Regular monitoring of specificity of PCRs for leishmaniasis
by processing blinded, negative specimen controls in parallel
with all steps utilized for clinical specimens and in each assay
warrants serious consideration (11, 25). To date, other evalu-
ations of PCR for CL have included reaction controls, but not
specimen controls (2, 4, 6, 8, 12, 16, 26, 27, 30, 34). A blinded
evaluation of samples distributed through a World Health Or-
ganization-sponsored Leishmania PCR network indicated that
false positives were unexpectedly high within several of the
participating molecular biology laboratories in Latin America
(L. Labrada, personal communication). In another study in
which 30 laboratories were sent blinded samples for evaluation
by PCR for Mycobacterium tuberculosis, the false-positive rate
ranged from 0 to 80% (22). It appears that the negative-
reaction controls used by these laboratories were not sufficient
to detect what occurred during sample preparation. These
multi-institutional studies demonstrate that a system of exter-
nal quality control is required before PCR methods can be
routinely incorporated into diagnostic strategies (22).
The advantages of PCR for the diagnosis of leishmaniasis
should be considered in the context of the existing diagnostic
services for CL and the clinical and epidemiological patterns
(5, 41). If most patients reside at some distance from reference
laboratories, the logistical problem of storing and shipping
frozen biopsies could be avoided by performing PCR on spec-
imens stored in lysis buffer at ambient temperatures, in etha-
nol, in paraffin-embedded biopsies, or on stained smears (1, 14,
19, 35). However, these more logistically feasible methods of
collecting and storing Leishmania PCR targets require further
evaluation before they can be used. Where an active case
detection program regularly identifies early cases, a micro-
scopic evaluation may suffice, provided that species identifica-
tion is not required for case management (27). PCR should be
used selectively, for chronic cases or when other assays are
negative. In areas in which several Leishmania species that
require different management are endemic, a PCR that both
detects and identifies kDNA should be utilized routinely (12,
26, 28).
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